Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).
No linked publications found in PubMed
Inclusion Criteria: * HIV positive * LPV/RTV-based HAART for at least 6 months * HIV-1 RNA less than 50c/mL (confirmed) * Non-HDL higher than 160 mg/dL * CD4 of at least 50 cells/mL Exclusion Criteria: * Use of lipid-lowering agents